Bulk Pharmaceutical API Sources for SIGNIFOR

Bulk Pharmaceutical API Sources for SIGNIFOR

Vendor	Vendor Homepage	Vendor Sku	API Url
BOC Sciences		820232-50-6
BenchChem		B609842
CymitQuimica		CQ_820232-50-6
MedChemexpress MCE		HY-16381B
AbaChemScene		CS-0082821
Starshine Chemical		2023-05-7C02340
EvitaChem		evt-278886

Bulk Active Pharmaceutical Ingredient (API) Sources for SIGNIFOR

Last updated: February 19, 2026

SIGNIFOR (pasireotide) is a somatostatin analog used for treating Cushing’s disease and certain types of neuroendocrine tumors. The bulk active pharmaceutical ingredient (API) for SIGNIFOR is pasireotide. Sourcing high-quality, compliant pasireotide API is critical for pharmaceutical manufacturers. This analysis identifies key API manufacturers and their relevant capabilities, regulatory standing, and geographical presence.

Who Manufactures Bulk Pasireotide API?

The manufacturing of pasireotide API is concentrated among a limited number of specialized pharmaceutical chemical companies. These manufacturers possess the complex synthesis capabilities and stringent quality control systems required for peptide-based APIs.

• Novartis AG: As the originator of SIGNIFOR, Novartis maintains significant control over its pasireotide API supply chain, potentially through internal manufacturing or closely managed contract manufacturing organizations (CMOs).
• Contract Manufacturing Organizations (CMOs) with Peptide Synthesis Expertise: Several global CMOs have the technical infrastructure and regulatory approvals to produce complex peptide APIs like pasireotide. Identifying specific CMOs requires in-depth supply chain intelligence and audit data, as these partnerships are often confidential. Companies specializing in peptide synthesis are the primary candidates.

What are the Regulatory Requirements for Pasireotide API?

Pasireotide API must adhere to rigorous regulatory standards set by global health authorities, including the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan.

• Current Good Manufacturing Practices (cGMP): API manufacturers must operate under cGMP guidelines. This ensures the identity, strength, quality, and purity of the API. Key aspects include:
  • Validated manufacturing processes.
  • Strict quality control and assurance systems.
  • Comprehensive documentation and traceability.
  • Controlled facilities and equipment.
  • Qualified personnel.
• Drug Master Files (DMFs) / Active Substance Master Files (ASMFs): Manufacturers typically file DMFs (in the U.S.) or ASMFs (in Europe) with regulatory authorities. These confidential documents provide detailed information about the API manufacturing process, facilities, and controls, allowing regulatory agencies to review the API's quality without disclosing proprietary information to the drug product applicant.
• Impurity Profiling: Rigorous analytical methods are required to identify and quantify impurities, including process-related impurities, degradation products, and residual solvents. ICH guidelines (e.g., ICH Q3A, Q3C) provide frameworks for managing these impurities.
• Stability Studies: Comprehensive stability data demonstrating the API's shelf-life under specified storage conditions is mandatory.

Where are Major Pasireotide API Manufacturing Facilities Located?

The geographical distribution of API manufacturing for complex molecules like pasireotide is influenced by specialized technical expertise, regulatory compliance capabilities, and cost-effectiveness.

Region	Key Countries with Peptide Synthesis Capabilities	Notes
Europe	Switzerland, Germany, Italy, France, Spain	Europe has a strong presence of established pharmaceutical companies and specialized CMOs with deep expertise in complex peptide synthesis and adherence to stringent EMA regulations. Many originator companies maintain API manufacturing within Europe.
North America	United States	The U.S. possesses advanced manufacturing capabilities and a robust regulatory framework (FDA). CMOs here often focus on high-value, complex APIs and cater to the demanding U.S. market.
Asia	India, China	India and China are significant global suppliers of APIs, with growing capabilities in complex synthesis. While many generic APIs originate from these regions, specialized peptide manufacturing for innovative drugs is increasing, though rigorous cGMP compliance and intellectual property considerations are paramount.

What are the Key Considerations for Sourcing Pasireotide API?

Sourcing pasireotide API involves a multi-faceted evaluation to ensure supply chain reliability, quality, and cost-effectiveness.

1. Quality and Regulatory Compliance

• cGMP Certification: The primary criterion is the manufacturer's adherence to cGMP. Audits of manufacturing sites are essential.
• DMF/ASMF Status: Availability and acceptance of the DMF/ASMF by the target regulatory agencies is critical for drug product approval.
• Analytical Capabilities: The manufacturer must possess advanced analytical laboratories capable of comprehensive impurity profiling, characterization, and release testing.
• Quality Agreements: A detailed Quality Agreement between the API supplier and the drug product manufacturer is mandatory, outlining roles, responsibilities, and quality standards.

2. Manufacturing Capacity and Reliability

• Production Scale: The manufacturer must demonstrate the capacity to meet projected demand for pasireotide API, from clinical trial quantities to commercial volumes.
• Contingency Planning: Suppliers should have robust business continuity plans to mitigate supply chain disruptions (e.g., geopolitical instability, natural disasters, regulatory actions).
• Lead Times: Understand and negotiate realistic lead times for API production and delivery.

3. Cost and Commercial Terms

• Pricing: API pricing is a significant component of the overall drug product cost. Benchmarking against similar complex peptide APIs can be informative.
• Payment Terms: Negotiate favorable payment terms.
• Intellectual Property (IP): For novel drug development or biosimilar manufacturing, understanding the IP landscape surrounding pasireotide synthesis is crucial.

4. Technical Expertise and Support

• Peptide Synthesis Specialization: Confirm the manufacturer's expertise in solid-phase peptide synthesis (SPPS) or other relevant advanced peptide manufacturing techniques, which are likely employed for pasireotide.
• Process Understanding: The supplier should have a deep understanding of the pasireotide synthesis route, including critical process parameters and potential risks.
• Technical Transfer: For new suppliers, a smooth and well-documented technical transfer process is vital.

Challenges in Pasireotide API Sourcing

The sourcing of pasireotide API presents several specific challenges due to its nature as a complex peptide.

• Synthetic Complexity: The multi-step synthesis of peptides can be intricate, involving protecting group strategies, coupling reactions, and purification challenges. This requires highly specialized expertise.
• Purity Requirements: Achieving high purity levels (>98-99%) for peptide APIs is often demanding, requiring sophisticated purification techniques like preparative High-Performance Liquid Chromatography (HPLC).
• Batch-to-Batch Consistency: Ensuring consistent peptide chain length, sequence fidelity, and impurity profiles across different manufacturing batches is critical and technically challenging.
• Analytical Method Development: Developing and validating robust analytical methods for characterizing complex peptide impurities and ensuring batch release can be resource-intensive.
• Supply Chain Vulnerability: Dependence on a limited number of specialized peptide manufacturers can create supply chain vulnerabilities. Dual sourcing strategies are often considered for critical APIs, though this can be challenging for highly specialized molecules.

Key Takeaways

• Pasireotide API manufacturing requires specialized peptide synthesis expertise and strict adherence to cGMP regulations.
• Key sourcing considerations include regulatory compliance (DMF/ASMF), manufacturing capacity, quality systems, and technical expertise.
• Geographical hubs for complex API manufacturing are present in Europe, North America, and increasingly in Asia.
• The synthetic complexity and stringent purity requirements of pasireotide pose significant sourcing challenges.
• Robust quality agreements and supply chain risk assessments are imperative for ensuring reliable access to pasireotide API.

Frequently Asked Questions

1. What is the typical synthesis route for pasireotide API? Pasireotide is a synthetic octapeptide. Its synthesis typically involves solid-phase peptide synthesis (SPPS) or a combination of solution-phase and solid-phase techniques, followed by extensive purification and characterization. The specific route employed by manufacturers is proprietary but generally involves sequential addition of amino acids with appropriate protecting groups.

2. How long does it take to develop a new supplier for pasireotide API? Developing a new supplier for a complex API like pasireotide can take 12-24 months or longer. This timeline includes supplier qualification, audits, technical transfer, analytical method validation, stability studies, and regulatory submissions (e.g., updating DMFs).

3. What are the main impurities to monitor in pasireotide API? Key impurities to monitor include deletion sequences (truncated peptides), incompletely deprotected peptides, epimerized amino acids, oxidized forms, and residual solvents or reagents used during synthesis and purification. Specific impurities will be detailed in the manufacturer's DMF/ASMF.

4. Can pasireotide API be sourced from China or India reliably for Western markets? Yes, API manufacturers in China and India can reliably supply pasireotide API for Western markets, provided they have achieved and maintain full cGMP compliance, have robust quality systems, and their DMFs/ASMFs are accepted by regulatory agencies like the FDA and EMA. Due diligence, including site audits, is critical.

5. What is the shelf life of pasireotide API, and how is it determined? The shelf life of pasireotide API is determined through comprehensive stability studies conducted according to ICH guidelines (e.g., ICH Q1A). These studies involve storing the API under various temperature and humidity conditions for extended periods and testing it at defined intervals for potency, purity, and degradation products. Typical shelf lives for such peptides, when stored appropriately, can range from 18 to 36 months.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Good Manufacturing Practice (GMP). Retrieved from https://www.fda.gov/drugs/guidance-compliance-regulatory-information/good-manufacturing-practice-gmp

[2] European Medicines Agency. (n.d.). Active substance master file procedure. Retrieved from https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-active-substance-master-file-procedure-scientific-advice-quality-non-clinical-and-quality_en.pdf

[3] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2015). ICH Harmonised Tripartite Guideline Impurities: Guidelines for Residual Solvents Q3C(R6). Retrieved from https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q3C/Q3C__R6_Step_4_2015_11_04.pdf

[4] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2006). ICH Harmonised Tripartite Guideline Impurities: Guidelines for New Drug Substances Q3A(R6). Retrieved from https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q3A/Step_4/Q3A_R6__Step4.pdf

[5] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2003). ICH Harmonised Tripartite Guideline Stability Testing of New Drug Substances and Products Q1A(R2). Retrieved from https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q1A/Step_4/Q1A_R2__Step4.pdf